Kinnevik is a leading growth investor, active owner, and operational partner that provides patient capital to challenger technology-enabled businesses in Europe and the US. They focus on supporting passionate founders who are building tomorrow's leaders within healthcare, software, and climate, with the goal of making everyday life easier and better for people around the world. Kinnevik invests at all stages of a company's growth journey, always determined to create long-term value. Kinnevik's investment philosophy emphasizes identifying companies with the potential to redefine industries and achieve remarkable growth. They seek out opportunities where technology can drive significant improvements and create lasting impact. This approach is reflected in their portfolio, which includes companies operating in sectors poised for disruption and growth. From the perspective of corporate governance, Kinnevik's Board of Directors is responsible for the overall strategy, integrating sustainability into value creation. The Audit & Sustainability Committee monitors the governance structures of investee companies, risk management, and compliance. Kinnevik's investment decisions are guided by a commitment to long-term value creation, responsible corporate governance, and a focus on sectors with significant growth potential, this is evident in their investment in Solugen to decarbonize the chemicals industry, their investment in Perk which is targeting the corporate travel industry and their focus on innovation in Healthcare with companies like Strand Therapeutics and Oviva.
Bevorzugte Reifephase für die erste Finanzierung.
Healthcare, Software, Climate
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
